The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunityChristina K. Baumgartner, Joshua H. Decker, Zhaoming Xiong et al.|Nature|2023Cited by 170
Balancing Proliferation with Igκ Recombination during B-lymphopoiesisKeith M. Hamel, Marcus R. Clark|Frontiers in Immunology|2014Cited by 18
Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complexQi Hao, Michael E. Kort, Manoj K Rathinaswamy et al.|Communications Chemistry|2024Cited by 9
Abstract 606: Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunityArvin Iracheta‐Vellve, Robert T. Manguso, Hakimeh Ebrahimi-Nik et al.|Cancer Research|2022Cited by 8
Abstract ND06: ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killingChristina K. Baumgartner, Philip R. Kym, Marcia N. Paddock et al.|Cancer Research|2022Cited by 7